WuXi Biologics (Cayman) Inc. (2269.HK)
HKD 22.85
(0.66%)
HKD 22.85
(0.66%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 17.03 Billion CNY | 11.56% |
| 2022 | 15.26 Billion CNY | 48.38% |
| 2021 | 10.29 Billion CNY | 83.35% |
| 2020 | 5.61 Billion CNY | 40.88% |
| 2019 | 3.98 Billion CNY | 57.18% |
| 2018 | 2.53 Billion CNY | 56.56% |
| 2017 | 1.61 Billion CNY | 63.68% |
| 2016 | 989.02 Million CNY | 77.55% |
| 2015 | 557.04 Million CNY | 67.86% |
| 2014 | 331.85 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.28 Billion CNY | 0.0% |
| 2024 Q1 | 4.28 Billion CNY | 0.37% |
| 2023 Q1 | 4.24 Billion CNY | 5.33% |
| 2023 Q3 | 4.27 Billion CNY | 0.59% |
| 2023 Q2 | 4.24 Billion CNY | 0.0% |
| 2023 FY | 17.03 Billion CNY | 11.56% |
| 2023 Q4 | 4.27 Billion CNY | 0.0% |
| 2022 Q3 | 4.03 Billion CNY | 11.88% |
| 2022 Q1 | 3.6 Billion CNY | 22.49% |
| 2022 FY | 15.26 Billion CNY | 48.38% |
| 2022 Q4 | 4.03 Billion CNY | 0.0% |
| 2022 Q2 | 3.6 Billion CNY | 0.0% |
| 2021 Q2 | 2.2 Billion CNY | 0.0% |
| 2021 Q3 | 2.94 Billion CNY | 33.51% |
| 2021 Q4 | 2.94 Billion CNY | 0.0% |
| 2021 FY | 10.29 Billion CNY | 83.35% |
| 2021 Q1 | 2.2 Billion CNY | 20.13% |
| 2020 Q3 | 1.83 Billion CNY | 88.69% |
| 2020 Q4 | 1.83 Billion CNY | 0.0% |
| 2020 Q2 | 972.05 Million CNY | 0.0% |
| 2020 Q1 | 972.05 Million CNY | -18.2% |
| 2020 FY | 5.61 Billion CNY | 40.88% |
| 2019 Q2 | 803.53 Million CNY | 0.0% |
| 2019 FY | 3.98 Billion CNY | 57.18% |
| 2019 Q4 | 1.18 Billion CNY | 0.0% |
| 2019 Q3 | 1.18 Billion CNY | 47.89% |
| 2019 Q1 | 803.53 Million CNY | 8.58% |
| 2018 FY | 2.53 Billion CNY | 56.56% |
| 2018 Q4 | 740.03 Million CNY | 0.0% |
| 2018 Q3 | 740.03 Million CNY | 40.37% |
| 2018 Q2 | 527.19 Million CNY | 0.0% |
| 2018 Q1 | 527.19 Million CNY | 9.29% |
| 2017 Q4 | 482.39 Million CNY | 0.0% |
| 2017 FY | 1.61 Billion CNY | 63.68% |
| 2017 Q2 | 327.02 Million CNY | 0.0% |
| 2017 Q1 | 327.02 Million CNY | 11.81% |
| 2017 Q3 | 482.39 Million CNY | 47.51% |
| 2016 Q2 | 205.06 Million CNY | 0.0% |
| 2016 Q4 | 292.47 Million CNY | 0.0% |
| 2016 FY | 989.02 Million CNY | 77.55% |
| 2016 Q1 | 205.06 Million CNY | 6.57% |
| 2015 Q3 | 139.26 Million CNY | 0.0% |
| 2015 Q2 | 139.26 Million CNY | 0.0% |
| 2015 Q1 | 139.26 Million CNY | 0.0% |
| 2015 FY | 557.04 Million CNY | 67.86% |
| 2015 Q4 | 192.42 Million CNY | 38.18% |
| 2014 Q4 | 139.26 Million CNY | 67.86% |
| 2014 Q1 | 82.96 Million CNY | 0.0% |
| 2014 Q3 | 82.96 Million CNY | 0.0% |
| 2014 FY | 331.85 Million CNY | 0.0% |
| 2014 Q2 | 82.96 Million CNY | 0.0% |
| 2013 Q4 | 82.96 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 484.71 Million HKD | -3414.261% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | -220.028% |